查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924756

固態腫瘤靶向蛋白市場：依適應症、標靶類別、治療方法和作用機制分類－2026-2032年全球預測

Solid Tumors Target Proteins Market by Indication, Target Class, Therapeutic Modality, Mechanism Of Action - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，固態腫瘤靶向蛋白市場價值將達到 16.2 億美元，到 2026 年將成長至 17.8 億美元，到 2032 年將達到 31.8 億美元，年複合成長率為 10.08%。

關鍵市場統計數據
基準年 2025 16.2億美元
預計年份：2026年 17.8億美元
預測年份 2032 31.8億美元
複合年成長率 (%) 10.08%

本文從戰略角度概述了正在重塑靶向蛋白在癌症治療中開發和臨床應用的科學、監管和商業趨勢的融合。

固態腫瘤標靶蛋白的治療模式正處於一個轉折點，科學創新、臨床緊迫性和商業性規範在此交匯，重新定義了腫瘤學的可能性。分子生物學、精準診斷和免疫調節的進步正在拓展可靶向靶點的選擇範圍，並迫使跨學科團隊重新思考標靶檢驗、試驗設計和價值實現。同時，監管機構和支付方對證據標準和真實世界治療結果提出了新的要求，這些要求在關鍵結果獲得之前就已影響研發決策。本導言將讀者置於這些動態的交會點，並簡明扼要地闡述了指導藥物發現、開發和商業化策略選擇的關鍵趨勢。

綜合審視重大科學突破、監管變革和資本配置調整，這些因素正在重新定義標靶腫瘤治療計畫的策略重點。

固態腫瘤靶向蛋白領域正經歷著一場變革性的轉變，其驅動力來自科學突破、監管政策的演變以及資金配置的調整。在科學層面，單細胞定序、空間生物學和系統免疫學以前所未有的解析度繪製了腫瘤異質性及其與微環境的相互作用圖譜。這些進展使得標靶選擇更加精準，並能設計出兼顧腫瘤內在抗藥性機制和免疫介導抗藥性機制的聯合治療策略。因此，傳統上依賴單一標靶單藥療法的治療方案正轉向多模態治療方法和適應性研發路徑。

對2025年美國關稅環境可能如何重塑癌症治療藥物開發商的供應鏈、監管合作和商業化準備全面評估

美國將於2025年生效的新關稅，除了直接的成本壓力外，還將為腫瘤治療藥物研發企業帶來一系列營運和策略方面的考量。生物製藥、抗體藥物複合體和關鍵試劑的供應鏈遍布全球，通常涉及多個跨境流程，包括原料採購、契約製造和分銷。因此，關稅調整可能會改變企業在近岸外包、雙重採購和庫存管理方面的獎勵。為此，各企業需要重新評估其供應商佈局，優先考慮生產的柔軟性，並加快二級供應商的合格，以避免下游臨床試驗和產品上市受到干擾。

簡潔、可操作的細分訊息，整合了適應症亞型、治療方式、標靶類別和作用機制，以最佳化研發優先排序和試驗設計。

了解市場區隔對於資源優先分配、使科學研究工作與臨床需求和商業性機會保持一致至關重要。根據適應症，市場涵蓋乳癌、大腸癌、肺癌、卵巢和攝護腺癌。乳癌進一步細分為HER2陽性、荷爾蒙受體陽性和三陰性亞型，而肺癌則細分為非小細胞肺癌和小細胞肺癌。這種細分有助於明確亞型特異性生物學和未滿足的需求如何指導標靶檢驗和試驗族群選擇。將治療假設與這些適應症和亞型相匹配，有助於研發人員調整註冊策略和生物標記開發，從而提高訊號檢測能力和監管審核準備。

區域比較分析：美洲、歐洲、中東和非洲以及亞太地區腫瘤計畫的臨床試驗能力、監管差異和商業化考量

區域趨勢對臨床開發、監管策略和商業化路徑有顯著影響。在美洲，完善的臨床試驗基礎設施和成熟的報銷體系為後期研究和早期商業化創造了有利環境。然而，研發者必須應對價格壓力和支付方對療效證據的要求，這些要求強調療效的比較。儘管某些適應症的區域生態系統支持快速招募患者，但申辦者仍應制定能夠預見不同支付方期望的准入策略，並酌情納入真實世界數據和基本契約。

競爭格局概述，重點介紹領先的製藥和創新生物技術公司的產品組合策略、合作活動和能力重點。

腫瘤領域的競爭格局呈現出大型製藥企業、靈活敏捷的生物技術公司和專業平台開發商並存的局面，它們都在競相將生物目標轉化為永續的患者獲益。成熟的腫瘤領域領導企業不斷利用其規模優勢、整合的研發能力和全球商業化網路，加速後期專案的進展並拓展至更廣泛的適應症。同時，新興生物技術公司透過專注的標靶發現、新型療法以及快速的、假設驅動的臨床開發來推動創新，並常常與大型公司建立策略合作夥伴關係和達成許可協議。

一系列具有重大影響的營運和策略優先建議，旨在加速臨床轉化、增強供應鏈韌性並明確腫瘤學領域的商業性差異化。

行業領導者必須採取果斷行動，將科學潛力轉化為持續的患者獲益和商業性成功。首先，他們應優先考慮具有強大轉化橋樑的項目，投資於早期生物標記檢驗、適應性試驗設計以及轉化終點，從而提高與監管機構和支付方評估標準明確匹配的可能性。加強轉化科學將降低後期試驗失敗率，並帶來更具吸引力的價值提案。其次，他們應透過合格多家契約製造組織 (CMO) 進行資格認證、探索區域生產夥伴關係關係以及在專案里程碑中納入緊急時應對計畫來增強供應鏈韌性，從而降低關稅和物流波動帶來的風險。

本文詳細概述了用於獲取腫瘤標靶蛋白可靠資訊的詳細調查方法，包括資料收集方法、分析框架和檢驗程序。

為確保結論的嚴謹性和可操作性，本研究採用結構化的分析架構整合了第一手和第二手資訊。第一手資料來源包括對臨床研究人員、監管專家和商業領袖的訪談，並輔以對同行評審文獻、臨床試驗註冊庫和已發布的監管指南的系統性回顧。第二手綜合分析則匯集了特定治療方法的研發模式、轉化生物標記證據以及已記錄的供應鏈實踐，建構了一個全面且檢驗的敘述，對從研發到商業化的決策者都具有參考價值。

簡明扼要的結論，整合了科學趨勢、監管發展和實際需要，旨在指導腫瘤學相關人員的決策。

總之，不斷演變的腫瘤生物學、日益成熟的標靶治療和免疫療法，以及全球研發領域不斷變化的營運現實，共同定義了腫瘤創新發展的下一階段。能夠將嚴謹的轉化證據與靈活的研發模式和穩健的供應鏈結合的機構將取得成功。監管環境和支付方越來越重視清晰的價值提案和可靠的真實世界證據計劃，這意味著臨床成功必須與從專案設計初期就採取的積極准入策略緊密相連。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章固態腫瘤靶向蛋白市場（依適應症分類）

  • 乳癌
    • HER2陽性
    • 荷爾蒙受體陽性
    • 三重否定
  • 大腸直腸癌
  • 肺癌
    • 非小細胞肺癌
    • 小細胞肺癌
  • 卵巢癌
  • 攝護腺癌

第9章固態腫瘤靶向蛋白市場依標靶分類

  • 查核點抑制劑
    • CTLA-4
    • PD-1
    • PD-L1
  • DNA修復蛋白
  • 生長因子受體
    • EGFR
    • HER2
    • VEGFR
  • 激酶抑制劑
    • 絲胺酸/蘇胺酸激酶抑制劑
    • 蛋白酪氨酸激酶抑制劑
  • 核受體

第10章固態腫瘤靶向蛋白市場（治療方法）

  • 抗體藥物複合體
  • CAR-T
  • 單株抗體
    • 嵌合體體
    • 完全人類
    • 人性化
  • 低分子化合物

第11章固態腫瘤靶向蛋白市場（依作用機制分類）

  • 變構抑制劑
  • DNA損傷劑
  • 荷爾蒙受體拮抗劑
  • 免疫查核點抑制劑
  • 受體蛋白酪氨酸激酶抑制劑

第12章固態腫瘤靶向蛋白市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章固態腫瘤靶向蛋白市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國固態腫瘤標靶蛋白市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國固態腫瘤靶向蛋白市場

16. 中國固態腫瘤靶向蛋白市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-7A380DA7C47F

The Solid Tumors Target Proteins Market was valued at USD 1.62 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 10.08%, reaching USD 3.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.62 billion
Estimated Year [2026] USD 1.78 billion
Forecast Year [2032] USD 3.18 billion
CAGR (%) 10.08%

A strategic orientation summarizing the converging scientific, regulatory, and commercial dynamics reshaping target protein development and clinical translation in oncology

The therapeutic landscape for solid tumor target proteins is at a pivotal juncture where scientific innovation, clinical urgency, and commercial discipline converge to redefine what is possible in oncology. Advances in molecular biology, precision diagnostics, and immune modulation have expanded the menu of actionable targets, prompting cross-disciplinary teams to rethink target validation, trial design, and value capture. Concurrently, regulatory agencies and payers are signaling new expectations around evidentiary standards and real-world outcomes, which influences go/no-go decisions long before pivotal readouts. This introduction situates readers at the intersection of these forces, providing a concise orientation to the major trends that inform strategic choices across discovery, development, and commercialization.

Through an integrated lens that spans biology, translational strategy, and market execution, this section foregrounds the primary vectors of change: deeper mechanistic understanding of tumor biology, the maturation of targeted and immune-based modalities, and the operational complexities of global development. The narrative that follows is structured to help senior leaders, clinical program directors, and commercial strategists quickly synthesize the implications of these dynamics and to identify where focused investment and disciplined stage-gating will yield the greatest returns. By emphasizing pragmatic translation and risk-managed innovation, this introduction prepares readers to evaluate subsequent sections with a clear sense of priority and context.

A synthesis of the major scientific breakthroughs regulatory changes and capital allocation shifts that are redefining strategic priorities in oncology target programs

The landscape for solid tumor target proteins has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and shifting capital allocation. At the scientific level, single-cell sequencing, spatial biology, and systems immunology have made it possible to map tumor heterogeneity and microenvironment interactions with unprecedented resolution. These advances enable finer-grained target selection and the design of combination strategies that account for both tumor-intrinsic and immune-mediated resistance mechanisms. As a result, programs that previously relied on single-target monotherapies are now pivoting toward multimodal regimens and adaptive development pathways.

Regulatory frameworks and payer expectations have become more sophisticated, rewarding programs that integrate biomarkers, companion diagnostics, and robust real-world evidence collection from the outset. This evolution accelerates approval pathways for agents that demonstrate clear patient-centered benefit, while raising the bar for long-term value demonstration. Investment patterns have also shifted: venture and corporate capital increasingly favor de-risked assets, platform technologies with broad applicability, and strategic alliances that can compress timelines and broaden market access. In combination, these forces are reshaping prioritization, encouraging cross-sector collaboration, and elevating translational rigor as the principal determinant of long-term success.

A comprehensive assessment of how the 2025 United States tariff environment may reshape supply chains regulatory collaborations and commercial readiness for oncology developers

The adoption of new tariff measures in the United States in 2025 introduces a set of operational and strategic considerations for oncology developers that extend beyond immediate cost pressures. Supply chains for biologics, antibody-drug conjugates, and critical reagents are global and often involve multiple cross-border steps including material sourcing, contract manufacturing, and distribution. Tariff adjustments can therefore alter incentives for nearshoring, dual-sourcing, and inventory management. In response, organizations must reassess supplier footprints, prioritize manufacturing flexibility, and accelerate qualification of secondary suppliers to avoid downstream trial and launch interruptions.

Beyond logistics, tariff-induced shifts can influence collaborative models and licensing negotiations. Partners and licensors will recalibrate risk-sharing frameworks to account for altered landed costs and timing uncertainty. Research collaborations that involve cross-border reagent transfers or multi-site manufacturing may require contractual amendments to reflect changing duties and customs regimes. Importantly, program leaders must differentiate short-term operational responses from longer-term strategic changes; while some adjustments are tactical, others create an inflection point to restructure supply networks, expand regional manufacturing capacity, and revisit channel economics for commercial launches. In short, tariffs in 2025 serve as a catalyst for greater supply resilience, more explicit contingency planning, and deeper alignment between commercial and manufacturing strategy.

Concise and actionable segmentation intelligence integrating indication subtype therapeutic modality target class and mechanism of action to optimize development prioritization and trial design

Understanding segmentation is essential to prioritize resources and to align scientific efforts with clinical need and commercial opportunity. Based on indication, the market is studied across breast cancer, colorectal cancer, lung cancer, ovarian cancer, and prostate cancer, with breast cancer examined further across HER2 positive, hormone receptor positive, and triple-negative subtypes, and lung cancer parsed into non-small cell lung cancer and small cell lung cancer; this granularity clarifies how subtype-specific biology and unmet need should guide target validation and trial population selection. By mapping therapeutic hypotheses to these indications and subtypes, developers can align enrollment strategies and biomarker development to improve signal detection and regulatory readiness.

Based on target class, programs are categorized across checkpoint inhibitors, DNA repair proteins, growth factor receptors, kinase inhibitors, and nuclear receptors, with checkpoint inhibitors explored across CTLA-4, PD-1, and PD-L1, growth factor receptors delineated into EGFR, HER2, and VEGFR, and kinase inhibitors further classified into serine/threonine and tyrosine kinase inhibitors; this classification helps R&D teams prioritize modality fit and combination hypotheses that address resistance biology. Based on therapeutic modality, research spans antibody-drug conjugates, CAR T, monoclonal antibodies, and small molecules, while monoclonal antibodies are differentiated into chimeric, fully human, and humanized constructs; this view supports decisions about manufacturing complexity, clinical development timelines, and differentiation strategies. Finally, based on mechanism of action, focus areas include allosteric inhibitors, DNA damage agents, hormone receptor antagonists, immune checkpoint blockers, and receptor tyrosine kinase inhibitors; coupling mechanism-level insights with indication and modality considerations yields a precise lens for portfolio rationalization and translational planning.

Comparative regional intelligence highlighting clinical trial capacity regulatory divergence and commercialization considerations across Americas EMEA and Asia Pacific for oncology programs

Regional dynamics exert a profound influence on clinical development, regulatory strategy, and commercialization pathways. In the Americas, robust clinical trial infrastructure and established reimbursement frameworks create a favorable environment for late-stage studies and early commercial rollout, yet developers must navigate pricing pressures and payer evidence requirements that emphasize comparative effectiveness. The regional ecosystem supports rapid enrollment for certain indications, but sponsors should plan for diverse payer expectations and develop access strategies that incorporate real-world evidence and outcomes-based contracting where appropriate.

In Europe, Middle East & Africa, regulatory heterogeneity and variable health system maturity require tailored market access approaches that balance centralized regulatory pathways with country-specific launch sequencing. Sponsors must calibrate value dossiers to local health economics expectations and design post-approval evidence generation programs that align with national payer priorities. The Asia-Pacific region presents a mix of high-capacity clinical sites, fast-growing biotech hubs, and divergent regulatory timelines; this creates opportunities to accelerate enrollment and regionally adapt development strategies, while also requiring attention to local manufacturing requirements, regulatory dossier localization, and culturally informed patient engagement. Across regions, strategic use of regulatory science, early payer dialogue, and adaptive commercialization planning will determine how rapidly and effectively therapies transition from trial success to patient impact.

High-level competitive landscape observations emphasizing portfolio strategy alliance activity and capability priorities among leading pharmaceutical companies and innovative biotechs

The competitive landscape in oncology is characterized by a mix of large pharmaceutical companies, nimble biotechs, and specialized platform developers, all competing to translate target biology into durable patient benefit. Established oncology leaders continue to leverage scale, integrated R&D capabilities, and global commercialization networks to accelerate late-stage programs and to execute broad label expansions. At the same time, emerging biotech firms drive innovation through focused target discovery, novel modalities, and rapid, hypothesis-driven clinical development that often culminates in strategic partnerships or licensing deals with larger collaborators.

Corporate strategy in this space increasingly emphasizes alliance activity, platform investments, and the pursuit of differentiated clinical niches rather than broad, undifferentiated indications. Companies that combine disciplined biomarker strategies with manufacturing agility and payer-aligned evidence generation gain a competitive edge. Portfolio managers are prioritizing assets with clear pathways to differentiation, durable responses, and manageable manufacturing profiles. For stakeholders, the primary implication is that competitive positioning hinges on an integrated capability set that spans translational science, clinical operations, regulatory strategy, and commercial access planning rather than on single-dimensional scientific novelty alone.

A prioritized set of high-impact operational and strategic recommendations to accelerate clinical translation enhance supply resilience and sharpen commercial differentiation in oncology

Industry leaders must act decisively to convert scientific promise into sustained patient impact and commercial success. First, prioritize programs with robust translational bridges by investing in early biomarker validation, adaptive trial designs, and translational endpoints that increase the probability of clear regulatory and payer-readout alignment. Strengthening translational science reduces late-stage attrition and enables more persuasive value narratives. Second, build supply resilience by qualifying multiple contract manufacturing organizations, exploring regional manufacturing partnerships, and embedding contingency planning into program milestones to mitigate tariff and logistics volatility.

Third, pursue pragmatic combination strategies that are biologically justified and operationally feasible, aligning trial designs with endpoints that matter to regulators and payers. Fourth, engage payers and health technology assessment bodies early to co-design evidence generation plans that address reimbursement criteria and to explore innovative contracting models that share risk and reward. Finally, foster strategic alliances that complement internal capabilities, whether through platform licensing, co-development agreements, or targeted acquisitions that accelerate access to complementary modalities and regional channels. Taken together, these recommendations create a cohesive roadmap for translating molecular insight into durable patient outcomes and commercial viability.

A detailed methodology summary explaining data collection approaches analytical frameworks and validation steps used to produce reliable insights on oncology target proteins

This research synthesizes primary and secondary inputs using structured analytical frameworks to ensure that conclusions are both rigorous and actionable. Primary data sources include expert interviews with clinical investigators, regulatory specialists, and commercial leaders, supported by systematic reviews of peer-reviewed literature, clinical trial registries, and public regulatory guidance. Secondary synthesis integrates modality-specific development patterns, translational biomarker evidence, and documented supply chain practices to construct holistically validated narratives that are relevant to decision-makers across R&D and commercial functions.

Analytical methods include cross-sectional mapping of indication-to-mechanism linkages, scenario analysis to stress-test supply chain and tariff impacts, and portfolio-level trade-off modeling to prioritize assets based on translational de-risking criteria rather than numeric market forecasts. Validation steps involve triangulating interview findings with documented trial outcomes and regulatory precedents, and conducting sensitivity checks to ensure that recommended actions hold up under plausible operational and policy shifts. The methodology emphasizes transparency, reproducibility, and direct applicability so that stakeholders can adapt the approach to their internal decision-making processes.

A concise integrative conclusion synthesizing scientific trends regulatory momentum and practical imperatives to guide decision-making for oncology stakeholders

In conclusion, the evolving science of tumor biology, the maturation of targeted and immune-based modalities, and the changing operational realities of global development collectively define the next phase of oncology innovation. Success will favor organizations that marry rigorous translational evidence with flexible development models and resilient supply chains. Regulatory and payer landscapes increasingly reward clearly articulated value propositions and robust real-world evidence plans, which means that clinical success must be paired with proactive access strategies from early stages of program design.

Moving forward, stakeholders should prioritize programs with strong mechanistic rationales, invest early in biomarker and diagnostic alignment, and design development pathways that anticipate regional regulatory and commercial nuances. By doing so, developers can maximize the likelihood that promising scientific discoveries translate into meaningful improvements in patient outcomes and sustainable business models. The integrated insights presented here offer a pragmatic compass for aligning scientific ambition with operational discipline and commercial realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solid Tumors Target Proteins Market, by Indication

  • 8.1. Breast Cancer
    • 8.1.1. Her2 Positive
    • 8.1.2. Hormone Receptor Positive
    • 8.1.3. Triple Negative
  • 8.2. Colorectal Cancer
  • 8.3. Lung Cancer
    • 8.3.1. Non-Small Cell Lung Cancer
    • 8.3.2. Small Cell Lung Cancer
  • 8.4. Ovarian Cancer
  • 8.5. Prostate Cancer

9. Solid Tumors Target Proteins Market, by Target Class

  • 9.1. Checkpoint Inhibitors
    • 9.1.1. Ctla-4
    • 9.1.2. Pd-1
    • 9.1.3. Pd-L1
  • 9.2. Dna Repair Proteins
  • 9.3. Growth Factor Receptors
    • 9.3.1. Egfr
    • 9.3.2. Her2
    • 9.3.3. Vegfr
  • 9.4. Kinase Inhibitors
    • 9.4.1. Serine Threonine Kinase Inhibitors
    • 9.4.2. Tyrosine Kinase Inhibitors
  • 9.5. Nuclear Receptors

10. Solid Tumors Target Proteins Market, by Therapeutic Modality

  • 10.1. Antibody Drug Conjugates
  • 10.2. Car T
  • 10.3. Monoclonal Antibodies
    • 10.3.1. Chimeric
    • 10.3.2. Fully Human
    • 10.3.3. Humanized
  • 10.4. Small Molecules

11. Solid Tumors Target Proteins Market, by Mechanism Of Action

  • 11.1. Allosteric Inhibitors
  • 11.2. Dna Damage Agents
  • 11.3. Hormone Receptor Antagonists
  • 11.4. Immune Checkpoint Blockers
  • 11.5. Receptor Tyrosine Kinase Inhibitors

12. Solid Tumors Target Proteins Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Solid Tumors Target Proteins Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Solid Tumors Target Proteins Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Solid Tumors Target Proteins Market

16. China Solid Tumors Target Proteins Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bayer AG
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Bristol-Myers Squibb Company
  • 17.11. Celgene Corporation
  • 17.12. Daiichi Sankyo Company, Limited
  • 17.13. Eli Lilly and Company
  • 17.14. Genentech, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Janssen Pharmaceuticals, Inc.
  • 17.17. Johnson & Johnson
  • 17.18. Merck & Co., Inc.
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Regeneron Pharmaceuticals, Inc.
  • 17.22. Roche Holding AG
  • 17.23. Sanofi
  • 17.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CTLA-4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY PD-L1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA REPAIR PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY EGFR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY VEGFR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SERINE THREONINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY NUCLEAR RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY DNA DAMAGE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY HORMONE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY IMMUNE CHECKPOINT BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY RECEPTOR TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 222. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 228. GCC SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 254. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 255. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 261. G7 SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 262. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 266. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 272. NATO SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY TARGET CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY GROWTH FACTOR RECEPTORS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA SOLID TUMORS TARGET PROTEINS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)